Aflibercept
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Aflibercept: VEGF-A/VEGF-B/PlGF trap → esotropia
One-Sentence Summary
Aflibercept is a VEGF-A/VEGF-B/PlGF trap, a biologic that blocks vascular endothelial growth factor signalling. The TxGNN model predicts it may be relevant to esotropia, but this rests on a model prediction only: 0 clinical trials and 0 publications were found to support it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | esotropia |
| TxGNN Prediction Score | 0.9938 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data |
| Number of Listed Products | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Aflibercept traps VEGF-A, VEGF-B and placental growth factor (PlGF), which reduces abnormal blood vessel growth and vascular leakage. Detailed mechanism of action data is not available in the data compiled for this report, so this description is based on general knowledge of the drug class.
Esotropia is an eye alignment disorder in which one or both eyes turn inward. It stems from problems in eye muscle control, nerve signalling or refractive and developmental factors, rather than from abnormal blood vessel growth. No plausible direct mechanism links VEGF blockade to esotropia.
The high TxGNN score (0.9938) is a statistical output of the model. It is not evidence of clinical benefit, and no study in the compiled data examines aflibercept in esotropia. The prediction should be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 72924 | Eylea 40mg/ml Injection | vial of 1 ml Injection | Not recorded in local data |
Aflibercept is marketed in India with one valid single-ingredient licence (manufacturer: Bayer Zydus Pharma Pvt Ltd). It is an injectable product.
Safety Considerations
- Drug Interactions: 78 potential interactions were identified. Major-level examples include deferiprone, samarium (153Sm) lexidronam, adalimumab, baricitinib, certolizumab pegol, cladribine and clozapine. Moderate-level examples include roflumilast, chloramphenicol, zidovudine, azathioprine, anakinra, alemtuzumab and several vaccines.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score. No clinical trials or publications address aflibercept in esotropia, and there is no plausible mechanistic link between VEGF blockade and an ocular motor alignment disorder. The evidence level is L5.
To proceed, the following is needed:
- Preclinical or mechanistic evidence linking VEGF/PlGF signalling to esotropia
- Detailed mechanism of action data
- Package insert warnings and contraindications for safety screening
- Assessment of route compatibility (intravitreal injection) with any proposed use in strabismus
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.